Lumosa Therapeutics Balance Sheet Health
Financial Health criteria checks 6/6
Lumosa Therapeutics has a total shareholder equity of NT$1.2B and total debt of NT$0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are NT$1.4B and NT$201.2M respectively.
Key information
0%
Debt to equity ratio
NT$0
Debt
| Interest coverage ratio | n/a |
| Cash | NT$555.62m |
| Equity | NT$1.18b |
| Total liabilities | NT$201.24m |
| Total assets | NT$1.38b |
Financial Position Analysis
Short Term Liabilities: 6535's short term assets (NT$733.5M) exceed its short term liabilities (NT$195.9M).
Long Term Liabilities: 6535's short term assets (NT$733.5M) exceed its long term liabilities (NT$5.3M).
Debt to Equity History and Analysis
Debt Level: 6535 is debt free.
Reducing Debt: 6535 has not had any debt for past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: 6535 has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: 6535 has sufficient cash runway for 1.9 years if free cash flow continues to reduce at historical rates of 14.4% each year.